ACADIA Pharmaceuticals Inc.
ACAD · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $958 | $726 | $517 | $484 |
| % Growth | 31.8% | 40.4% | 6.8% | – |
| Cost of Goods Sold | $82 | $46 | $10 | $19 |
| Gross Profit | $876 | $681 | $507 | $465 |
| % Margin | 91.5% | 93.7% | 98% | 96% |
| R&D Expenses | $303 | $352 | $362 | $239 |
| G&A Expenses | $0 | $393 | $0 | $396 |
| SG&A Expenses | $488 | $402 | $369 | $396 |
| Sales & Mktg Exp. | $0 | $9 | $0 | $0 |
| Other Operating Expenses | -$147 | $0 | $0 | $0 |
| Operating Expenses | $645 | $754 | $731 | $635 |
| Operating Income | $231 | -$73 | -$224 | -$170 |
| % Margin | 24.1% | -10.1% | -43.2% | -35.2% |
| Other Income/Exp. Net | $27 | $22 | $10 | $3 |
| Pre-Tax Income | $258 | -$51 | -$213 | -$168 |
| Tax Expense | $32 | $10 | $3 | $0 |
| Net Income | $226 | -$61 | -$216 | -$168 |
| % Margin | 23.6% | -8.4% | -41.8% | -34.7% |
| EPS | 1.37 | -0.37 | -1.34 | -1.05 |
| % Growth | 470.3% | 72.4% | -27.6% | – |
| EPS Diluted | 1.36 | -0.37 | -1.34 | -1.05 |
| Weighted Avg Shares Out | 166 | 164 | 162 | 160 |
| Weighted Avg Shares Out Dil | 166 | 164 | 162 | 160 |
| Supplemental Information | – | – | – | – |
| Interest Income | $25 | $17 | $7 | $1 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $16 | $6 | $2 | $3 |
| EBITDA | $100 | -$68 | -$222 | -$167 |
| % Margin | 10.5% | -9.3% | -42.8% | -34.5% |